Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

NovoCure Ltd Director's Dealing 2023

Dec 20, 2023

31949_dirs_2023-12-20_a1d27dcf-e062-448e-93f8-9f131214eb2b.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2023-07-26

Reporting Person: Giladi Moshe (N/A)

Holdings (Non-Derivative)

Security Shares Ownership
Ordinary Shares 7008.00 Direct
Restricted Share Units 6496.00 Direct
Restricted Share Units 2983.00 Direct
Restricted Share Units 1653.00 Direct
Restricted Share Units 154.00 Direct
Restricted Share Units 353.00 Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Stock Options (Right to buy) $153.09 2031-03-01 Ordinary Shares (1951.00) Direct
Stock Options (Right to buy) $107.73 2031-11-01 Ordinary Shares (831.00) Direct
Stock Options (Right to buy) $83.77 2032-05-02 Ordinary Shares (7693.00) Direct
Stock Options (Right to buy) $80.59 2032-02-29 Ordinary Shares (4346.00) Direct
Stock Options (Right to buy) $77.49 2029-11-05 Ordinary Shares (833.00) Direct
Stock Options (Right to buy) $76.97 2033-02-27 Ordinary Shares (10804.00) Direct
Stock Options (Right to buy) $69.37 2030-03-02 Ordinary Shares (2779.00) Direct
Stock Options (Right to buy) $47.04 2029-03-21 Ordinary Shares (2822.00) Direct
Stock Options (Right to buy) $21.15 2028-02-26 Ordinary Shares (3451.00) Direct
Stock Options (Right to buy) $7.15 2027-02-21 Ordinary Shares (6875.00) Direct

Footnotes

F1: Represents restricted share units that are scheduled to vest in equal installments on February 28, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates.

F10: Currently exercisable.

F11: Options to buy 10,804 ordinary shares will vest in equal installments on each of February 28, 2024, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates.

F12: Options to buy 2,779 ordinary shares, 2,085 shares of which are currently exercisable and the remainder will vest on March 3, 2024, subject to the reporting person's continued employment through such date.

F2: Represents restricted share units that are scheduled to vest in equal installments on May 3, 2024 and 2025, subject to the reporting person's continued employment through such dates.

F3: Represents restricted share units that are scheduled to vest in equal installments on March 1, 2024 and 2025, subject to the reporting person's continued employment through such dates.

F4: Represents restricted share units that are scheduled to vest in equal installments on November 2, 2024, subject to the reporting person's continued employment through such date.

F5: Represents restricted share units that are scheduled to vest in equal installments on March 2, 2024, subject to the reporting person's continued employment through such date.

F6: Options to buy 1,951 ordinary shares, 976 shares of which are currently exercisable and the remainder will vest in equal installments on each of March 2, 2024 and 2025, subject to the reporting person's continued employment through such dates.

F7: Options to buy 831 ordinary shares, 416 shares of which are currently exercisable and the remainder will vest in equal installments on each of November 2, 2024 and 2025, subject to the reporting person's continued employment through such dates.

F8: Options to buy 7,693 ordinary shares, 1,924 shares of which are currently exercisable and the remainder will vest in equal installments on each of May 3, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates.

F9: Options to buy 4,346 ordinary shares, 1,087 shares of which are currently exercisable and the remainder will vest in equal installments on each of March 1, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates.